Transfusion Journal Citation Rate 2026
0041-1132
eISSN 1537-2995
Wiley
US
Q3 Quartile Verified Publisher
About Transfusion
Transfusion (T) is a peer-reviewed academic journal, published by Wiley in US. It is catalogued under ISSN 0041-1132 (electronic ISSN 1537-2995).
Transfusion Citation Rate 2026 — In Context
Transfusion has a 2025 2-Year Citation Rate (OpenAlex) of 1.38, placing it in the Q3 quartile. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not a OpenAlex Journal Impact Factor.
Transfusion operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view.
Researchers looking to publish in Transfusion should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Transfusion against similar journals in the field, use our journal comparison tool.
Submission Tips for Transfusion
- Budget $3900 for the Article Processing Charge. Check if your institution or funder covers OA fees.
| ISSN (Print) | 0041-1132 |
|---|---|
| ISSN (Online) | 1537-2995 |
| Publisher | Wiley |
| Country | United States |
| APC / Cost | $3900 USD |
In-depth profile & metrics
Transfusion is published by Wiley and based in United States. It runs on a subscription or hybrid model with an article-processing charge of USD 3900.
Transfusion is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.
Its most recent citation rate stands at 1.379.
Links
Continue on JournalsHub
Put what you just read into practice with these free tools.
Frequently Asked Questions about Transfusion
Live Indexing Status
Updated April 2026Track real-time indexing metrics to ensure this journal meets your academic requirements.
Citation Rate
Historical Trend
Initial data points onlyCitation Rate by Year
| Year | Value | Source |
|---|---|---|
| 2025 | 1.379 | 2-Year Mean Citedness (OpenAlex) |
Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.
Research Highlights
Recently published high-impact papers in this journal:
-
Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?
Musab M. A. Omar, Majed A Alanazi, Denise E. Jackson • 2026
Explore More Journals
Metadata
Last updated: Apr 24, 2026
Updated by: openalex_bulk
OpenAlex ID: S186746772
Get weekly updates
Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.